SWOG clinical trial number
CTSU/EA2174
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Open
Phase
Abbreviated Title
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Status Notes
Kaitlyn J. Kelly, MD SWOG Champion
Activated
01/17/2019
Treatment
Paclitaxel
Carboplatin
Ipilimumab
Nivolumab
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.